Video
Dr. Philip on Olaratumab for Soft Tissue Sarcoma
Author(s):
Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.
Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.
Trabectedin (Yondelis) received FDA approval for liposacoma and leiomyosarcoma, while the breast cancer agent eribulin (Halaven) is being studied in soft tissue sarcoma.
An agent being investigated in an ongoing phase III trial is olaratumab in combination with doxorubicin in advanced soft tissue sarcoma, which has demonstrated promising early-phase data. Olaratumab is a novel agent that could potentially be one of the first new drugs to add benefit to doxorubicin, which has been a standard treatment for several years.
<<<
